skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
Nanosomal Docetaxel Lipid Suspension (Code C111570)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Nanosomal Docetaxel Lipid Suspension

Definition: A lipid-based nanosomal formulation of the poorly soluble, semi-synthetic, second-generation taxane docetaxel, with potential antineoplastic activity. Upon intravenous injection, docetaxel binds to and stabilizes tubulin, which inhibits microtubule disassembly and results in both cell cycle arrest at the G2/M phase and cell death. This liposomal formulation solubilizes docetaxel without the use of toxic solvents, such as polysorbate 80. This permits the administration of larger doses of docetaxel and improves the drug's safety profile by avoiding solvent-associated toxicities, such as hypersensitivity reactions and neurotoxicity. In addition, the nanosomal lipid-based delivery of docetaxel improves drug penetration into tumors and decreases drug clearance, all of which prolong the duration of docetaxel's therapeutic effects.

Display Name: Nanosomal Docetaxel Lipid Suspension

Label: Nanosomal Docetaxel Lipid Suspension

NCI Thesaurus Code: C111570 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: CL453978  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
Nanosomal Docetaxel Lipid Suspension

External Source Codes: 
PDQ Closed Trial Search ID 752055
PDQ Open Trial Search ID 752055 (check for NCI PDQ open clinical trial info)

Other Properties:
     Name Value (qualifiers indented underneath)
code C111570
Contributing_Source CTRP
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom